Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC-Reference-Cited by-同舟云学术

Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC

Published:2024-07-30 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Hussein-Agha Rim^ORCID,Kannengiesser Caroline^ORCID,Lainey Elodie,Marcais Ambroise^ORCID,Srour Micha,Sterin Arthur,Buchbinder Nimrod,Borie Raphael,Plessier Aurelie,Socié Gerard^ORCID,Peffault de Latour Regis,Sicre de Fontbrune Flore^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02381-5.pdf

Reference15 articles.

1. Revy P, Kannengiesser C, Bertuch AA. Genetics of human telomere biology disorders. Nat Rev Genet. 2023;24:86–108.

2. Rocha V, Devergie A, Socié G, Ribaud P, Espérou H, Parquet N, et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol. 1998;103:243–8.

3. Tummala H, Walne A, Dokal I. The biology and management of dyskeratosis congenita and related disorders of telomeres. Expert Rev Hematol. 2022;15:685–96.

4. Marsh JC, Pearce RM, Koh MBC, Lim Z, Pagliuca A, Mufti GJ, et al. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49:42–8.

5. Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O’Brien TA, et al. A reduced-intensity conditioning regimen for patients with dyskeratosis congenita undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22:884–8.